Veru (VERU) Q1 2025 earnings summary

Executive summary

• Completed sale of FC2 female condom business for $18 million, marking a strategic shift to focus on late-stage biopharmaceutical development, primarily enobosarm and sabizabulin for cardiometabolic and inflammatory diseases.

• Announced positive topline results from Phase 2b QUALITY study for enobosarm (with semaglutide), meeting primary and key secondary endpoints, including significant preservation of lean mass and enhanced fat loss in older obese patients on GLP-1 therapy.

• Independent Data Monitoring Committee recommended continuation of the QUALITY extension study after safety review.

• Announced new cardiometabolic indication for sabizabulin targeting inflammation in atherosclerotic cardiovascular disease.

• Company is not profitable, has negative cash flow from operations, and faces substantial doubt about its ability to continue as a going concern for the next 12 months.

Financial highlights

• Net loss from continuing operations was $1.8 million ($0.01 per diluted share), improved from $7.7 million loss in the prior year's quarter; total net loss increased to $8.9 million ($0.06 per share) from $8.3 million ($0.08 per share).

• Net loss from discontinued operations (FC2 business) was $7.1 million, including a $4.2 million loss on sale.

• Cash, cash equivalents, and restricted cash totaled $26.6 million as of December 31, 2024, up from $24.9 million at September 30, 2024.

• Research and development expenses rose to $5.7 million from $1.7 million year-over-year, mainly due to enobosarm clinical study expenses.

• Selling, general and administrative expenses decreased to $5.2 million from $6.7 million year-over-year.

Outlook and guidance

• Sufficient capital to fund operations through the end of 2025, covering the enobosarm phase II-B extension study data readout, but additional capital will be needed for ongoing drug development.

• Topline results from the Phase 2b QUALITY extension study expected in Q2 2025.

• Plans to request end-of-Phase 2 meeting with FDA for enobosarm and advance to Phase 3 study with 52-week treatment duration.

• Developing a novel modified release oral formulation of enobosarm, with Phase 1 bioavailability trial anticipated in H1 2025.

• Sabizabulin Phase 2 proof-of-concept study for atherosclerotic coronary artery disease under consideration, with IND submission planned for H1 2026, subject to funding.